Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Cough severity represents an important end-point to assess the impact of therapies for patients with refractory chronic cough (RCC). Our objective was to develop a new patient-reported outcome measure addressing cough severity in patients with RCC.

Methods: Phase 1 (item generation): a systematic survey, focus groups and expert consultation generated 51 items. Phase 2 (item reduction): from a list of 51 items, 100 patients identified those they had experienced in the previous year and rated their importance on a 5-point scale. The McMaster Cough Severity Questionnaire (MCSQ) included items reported to occur most frequently and that had the highest importance scores. Patient feedback on the MCSQ led to elimination of redundant items. Another 100 patients completed the MCSQ, from which we performed an exploratory factor analysis and a Rasch analysis to further refine items on the MCSQ.

Results: Previous publications report on the details of Phase 1. Phase 2 led to selection of 15 items from the initial 51. Patient feedback on the 15 items led to elimination of five redundant items. An exploratory factor analysis of the 10-item MCSQ led to the selection of two domains, and the elimination of one item that demonstrated cross-loading and another that had high inter-item correlations. A Rasch analysis of the 8-item MCSQ confirmed that the response options functioned in a logically progressive manner and that no items exhibited differential item functioning. The final 8-item MCSQ has a 1-week recall period and includes two domains (intensity and frequency). The 8-item MCSQ had high internal consistency (Cronbach's α=0.89), proved able to distinguish different levels of cough severity (person separation index 0.89) and demonstrated high cross-sectional convergent validity (Pearson's correlation 0.76, 95% CI 0.66-0.83) with the 100-mm cough severity visual analogue scale.

Conclusions: Initial evidence supports the validity of the MCSQ, an 8-item instrument measuring cough severity in patients with RCC. Future studies should evaluate its properties in measuring change over time.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11799886PMC
http://dx.doi.org/10.1183/13993003.01565-2024DOI Listing

Publication Analysis

Top Keywords

cough severity
32
8-item mcsq
12
mcsq
9
cough
9
items
9
mcmaster cough
8
severity
8
severity questionnaire
8
questionnaire mcsq
8
patients refractory
8

Similar Publications

ObjectiveThe sedation protocol for flexible fiberoptic bronchoscopy has long been a matter of inconclusiveness. The aim of this study was to evaluate the safety and efficacy of remimazolam combined with alfentanil in flexible fiberoptic bronchoscopy and provide insights for optimizing clinical anesthesia strategies.MethodsThis study was a randomized, single-blind controlled trial.

View Article and Find Full Text PDF

Hydralazine is an antihypertensive that can induce immune-related adverse effects, such as hydralazine-induced lupus and hydralazine-induced antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis (AAV). AAV involves necrotizing inflammation of small blood vessels, manifesting as fever, malaise, arthralgia, and myalgia, potentially leading to organ failure. Diagnosis includes clinical evaluation, serological testing for ANCA, and histopathological examination, confirmed by necrotizing granulomatous inflammation in affected tissues.

View Article and Find Full Text PDF

Immune reconstitution inflammatory syndrome (IRIS) is commonly described in individuals recovering from immunosuppression, particularly in HIV-positive patients initiating antiretroviral therapy. However, a similar rebound phenomenon can occur postpartum, a period marked by a shift from an immunotolerant to a pro-inflammatory state. IRIS in this context is underrecognized and may present atypically, complicating timely diagnosis.

View Article and Find Full Text PDF

Vaping product use-associated lung injury is a recently recognized respiratory illness that can occur in users of e-cigarettes or vaping products, including those marketed as nicotine‑free. We describe a previously healthy, 22‑year‑old male, non‑smoker who presented with progressive shortness of breath, non‑productive cough, pleuritic chest pain, low‑grade fever, and fatigue. He reported daily use of a flavored nicotine‑free vaping device for eight months, with increased use in the preceding month, including cartridges purchased from unregulated online sources.

View Article and Find Full Text PDF

Mirtazapine 30 mg as a Potential New Therapy for the Treatment of Laryngeal Sensory Neuropathy.

J Voice

September 2025

Department of Otorhinolaryngology, Faculty of Medicine, Minia University, Minia, Egypt . Phoniatric unit,ENT department, Faculty of Medicine, Minia University, Minia, Egypt. Electronic address:

Objective: Laryngeal sensory neuropathy (LSN) is an irritating laryngeal disorder that may cause intractable cough, globus sensation, and frequent throat clearing. The diagnosis is typically done by exclusion, even if the postulated etiologies are viral, allergic, or idiopathic. The study aims to introduce mirtazapine 30 mg as a potential new therapy.

View Article and Find Full Text PDF